Abstract:Background Frontotemporal lobar degeneration (FTLD) is second only to Alzheimer’s disease as a cause of dementia, and we find the scaffolding protein β‐arrestin2 is elevated in human brains with this condition, and is responsible for accumulation of pathological tau tangles. Increased β‐arrestin2 impairs tau clearance and promotes tau aggregation by impeding the autophagy cargo carrier p62/SQSTM1. Such activity requires β‐arrestin2 in its oligomeric form, an assembly state that is not involved with receptor binding. Virus delivered gene therapy to the brain with dominant‐negative mutant β‐arrestin2s ablates pathologic tau in neurons of a mouse model of FTLD‐tau, revealing a new strategy to mitigate tauopathy by targeting β‐arrestin2 oligomerization. Method mice: Arrb2 − / − , tau P301S, and WT mice were all bred in the C57BL6 background. Patients samples: Frozen frontal cortex tissue samples were obtained from the Alzheimer’s Disease Research Center at Emory University. We used samples from FTLD‐tau diagnosed patients. Primary neuronal cultures, Proximity ligation assay (PLA), Immunocytochemistry and Immunohistochemistry, Sarkosyl extraction, Generation of rAAV9 and stereotaxic injections, Electrophysiology, and Atomic force Microscopy Imaging applications were used in this study. Result β‐arrestin2 levels in brains of FTLD‐tau patients and tau P301S transgenic mice were significantly increased. β‐arrestin2 increases tau stability without altering tau mRNA levels. Furthermore, genetic reduction of β‐arrestin2 mitigates tauopathy and synaptic dysfunction in tau P301S mice. β‐arrestin2 oligomerization is required for tau stability, and β‐arrestin2 oligomers increase tau levels by inhibiting self‐association of the autophagy cargo receptor p62/SQSTM1, impeding p62 autophagy flux. Hence, reduction of oligomerized β‐arrestin2 with virus encoding β‐arrestin2 mutants acting as dominant‐negatives markedly reduced tau‐laden neurofibrillary tangles in FTLD mice in vivo . Reducing β‐arrestin2 oligomeric status represents a new strategy to alleviate tau pathology in FTLD and related tauopathies. Conclusion Based on our findings, the effects of inhibiting β‐arrestin2 oligomerization would be expected to not only inhibit the development of new tau tangles, but also to clear existing tau accumulations due to this mechanism of enhancing tau clearance. Beyond tauopathy, it is conceivable that this strategy could also prove to be beneficial in other neurodegenerative diseases bearing proteinopathies that are cleared via p62.

The multifaceted functions of β-arrestins and their therapeutic potential in neurodegenerative diseases

Β-Arrestins As Potential Therapeutic Targets for Alzheimer’s Disease

-arrestin1 promotes tauopathy by transducing GPCR signaling, disrupting microtubules and autophagy

Phospho-selective Mechanisms of Arrestin Conformations and Functions Revealed by Unnatural Amino Acid Incorporation and 19F-NMR

Insight into the regulatory mechanism of β-arrestin2 and its emerging role in diseases

Therapeutic Potential of Targeting ß-Arrestin

Classical and new roles of β-arrestins in the regulation of G-PROTEIN-COUPLED receptors

β-Arrestin Based Receptor Signaling Paradigms: Potential Therapeutic Targets for Complex Age-Related Disorders

The role and mechanism of β-arrestin2 in signal transduction

Opposing functions of β-arrestin 1 and 2 in Parkinson’s disease via microglia inflammation and Nprl3

Functional Specialization of Β-Arrestin Interactions Revealed by Proteomic Analysis

β-arrestin2: an emerging player and potential therapeutic target in inflammatory immune diseases

β-Arrestin2 oligomers impair the clearance of pathological tau and increase tau aggregates

Involvement of Β-Arrestins in Cancer Progression

Β-Arrestins: Multifunctional Signaling Adaptors in Type 2 Diabetes.

Progress studing in the role of arrestins

A Small Family of Multi-Functional Proteins

β-Arrestins 1 and 2 are critical regulators of inflammation

Roles of Beta-Adrenergic Receptors in Alzheimer'S Disease: Implications for Novel Therapeutics

Arrestins contribute to amyloid beta-induced cell death via modulation of autophagy and the α7nAch receptor in SH-SY5Y cells

β‐arrestin2 oligomers impair the clearance of pathological tau and increase tau aggregates: Molecular and cell biology: Tau‐related mechanisms